UroGen Pharma Ltd

UroGen Pharma Ltd

URGN

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.37B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
UroGen Pharma LtdUroGen Pharma Ltd-10.6-107%13.3-1.7
$42.50

Target Price by Analysts

59.8% upsideUroGen Pharma Target Price DetailsTarget Price
$15.60

Current Fair Value

41.3% downside

Overvalued by 41.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.37 Billion
Enterprise Value$1.46 Billion
Dividend Yield$- (-)
Earnings per Share$-3.19
Beta1.59
Outstanding Shares50,182,758

Return

Return on Equity107.22%ROE
Return on Assets-52.51%
Return on Invested Capital-55.46%

Valuation & Multiples

P/E Ratio-10.6P/E Ratio
PEG22.92PEG
Price to Sales13.3Price to Sales
Price to Book Ratio-8.87Price to Book Ratio
Enterprise Value to Revenue10.42
Enterprise Value to EBIT-13.01
Enterprise Value to Net Income-11
Total Debt to Enterprise0.14
Debt to Equity-1.65Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 11, 2026
EPS Estimate
$-0.48
Average shareholder expectation
Revenue Estimate
$44.83 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 6, 2026
EPS Estimate
$-0.30
Average shareholder expectation
Revenue Estimate
$61.60 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.7613▲ 60.73%
Total Calls226,200▼ 83.42%
Total Puts172,200▼ 18.04%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %94.29%▲ 3.34%
Total Invested$834.80M▼ 18.44%
Investors Holding177▲ 2.00%

ESG Score

No data

About UroGen Pharma Ltd

CEO: Elizabeth Barrett